Melanocortin receptor antagonists and modulations of melanocortin receptor activity
US6953779B2 · kind B2 · utility
3Cited by
7References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 4, 2001 |
| Grant date | Oct 11, 2005 |
| Priority date | — |
| Expiry date | Jan 7, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The clinical outcome of disseminated melanoma is grim. Small molecular weight antagonists (preferably about seven amino acid residues) specific for MCR on melanoma cells are provided for the therapy of melanoma as well as in other conditions where modulation of MCR is of clinical significance. A particularly preferred antagonist is p-anisoyl-[D-Arg6,9, D-Lys11, D-Leu12] dynorphin A(6-12)-NH2, which is an excellent antagonist of the MCR-1 receptor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.